Cancer Immunotherapy Drug Discovery Outsourcing Market Report 2026

Cancer Immunotherapy Drug Discovery Outsourcing Market Overview

• Cancer Immunotherapy Drug Discovery Outsourcing market size has reached to $1.66 billion in 2025 • Expected to grow to $2.64 billion in 2030 at a compound annual growth rate (CAGR) of 9.4% • Growth Driver: High R&D Costs Fueling Growth in Cancer Immunotherapy Drug Discovery Outsourcing Market • Market Trend: Strategic Partnerships Driving Growth In Cancer Immunotherapy Drug Discovery Outsourcing: Charles River And Parker Institute Collaboration • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cancer Immunotherapy Drug Discovery Outsourcing Market?

Cancer immunotherapy drug discovery outsourcing is a specialized service model in the pharmaceutical and biotech sectors. It entails delegating aspects of cancer immunotherapy drug development to external service providers, typically contract research organizations (CROs) or contract development and manufacturing organizations (CDMOs) to speeds up innovation by leveraging external expertise and resources, letting pharmaceutical companies focus on core activities. The main drug types of cancer immunotherapy drug discovery outsourcing are monoclonal antibodies, immunomodulators, oncolytic viral therapies and cancer vaccines, and others. Monoclonal antibodies refers to laboratory-made molecules that mimic the immune system's ability to fight off harmful pathogens by targeting specific proteins on cancer cells. The services include target identification and validation, lead screening and characterization, and cell-based assays used in therapeutic areas such as lung cancer, breast cancer, melanoma, and others.

What Is The Cancer Immunotherapy Drug Discovery Outsourcing Market Growth Forecast?

The cancer immunotherapy drug discovery outsourcing market size is expected to see strong growth in the next few years. It will grow to $2.64 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to accelerated demand for precision immuno-oncology therapies, increasing biotech startup formation, growing complexity of immunotherapy modalities, pressure to shorten drug development timelines, rising investment in outsourced discovery services. Major trends in the forecast period include rising outsourcing of early-stage immunotherapy research, growing demand for specialized CRO expertise, expansion of cell-based and immune assay services, increased collaboration between pharma and biotech firms, accelerated development of next-generation immunotherapies.

Global Cancer Immunotherapy Drug Discovery Outsourcing Market Segmentation

1) By Drug Type: Monoclonal Antibodies, Immunomodulators, Oncolytic Viral Therapies And Cancer Vaccines, Other Drug Types 2) By Service Type: Target Identification And Validation, Lead Screening And Characterization, Cell-Based Assays 3) By Therapeutic Area: Lung Cancer, Breast Cancer, Melanoma, Other Therapeutic Areas Subsegments: 1) By Monoclonal Antibodies: Checkpoint Inhibitors, Therapeutic Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs) 2) By Immunomodulators: Cytokines, Immune Checkpoint Modulators, Toll-Like Receptor Agonists, Immune Adjuvants 3) By Oncolytic Viral Therapies And Cancer Vaccines: Oncolytic Virus-Based Therapies, Cancer Vaccines, Viral Vectors For Immunotherapy 4) By Other Drug Types: Adoptive Cell Therapy, Immune Cell Modulators, Small Molecule Immune Modulators, Gene Editing And Immunotherapy

What Are The Drivers Of The Cancer Immunotherapy Drug Discovery Outsourcing Market?

The high cost of research and development is expected to propel the growth of the cancer immunotherapy drug discovery outsourcing market going forward. Research and development costs refer to the substantial investment required for scientific expertise, advanced laboratory infrastructure, complex technologies, and high-risk innovation processes. R&D costs continue rising due to increasing scientific complexity and the need for highly specialized capabilities. The cancer immunotherapy drug discovery outsourcing market supports pharmaceutical and biotechnology companies by enabling cost-efficient access to advanced research resources through contract research organizations (CROs). For instance in August 2025 accroding to the The Office for National Statistics (ONS) a UK-based Statistics Authority in 2023, expenditure on research and development (R&D) performed in the UK amounted to $95.2 billion, an increase of $3.93 billion in current prices since 2022. Therefore, the high cost of in-house research and development is driving the growth of the cancer immunotherapy drug discovery outsourcing industry. The rise in cancer incidence is expected to propel the growth of the cancer immunotherapy drug discovery outsourcing market going forward. Cancer incidence refers to the number of new cases of cancer diagnosed in a specific population during a defined period of time. The rising consumption of tobacco and alcohol and the prevalence of smoking contribute to the growth in the number of cancer cases across the globe. Cancer immunotherapy drug discovery outsourcing supports the fight against rising cancer incidence by accelerating the development of targeted therapies that improve treatment outcomes and patient survival. For instance, in September 2025, according to Cancer Research UK, a UK-based charity, from 2024 to 2026, the incidence rate of leukemia in the UK is estimated at approximately 17.9 cases per 100,000 people per year, and it is projected to decrease by 3% to around 17.4 per 100,000 by 2038 to 2040. Therefore, the rise in cancer incidence is driving the growth of the cancer immunotherapy drug discovery outsourcing industry.

Key Players In The Global Cancer Immunotherapy Drug Discovery Outsourcing Market

Major companies operating in the cancer immunotherapy drug discovery outsourcing market are Thermo Fisher Scientific Inc., Danaher Corporation, Laboratory Corporation of America Holdings (LabCorp), Eurofins Scientific SE, WuXi AppTec Co Ltd., Charles River Laboratories International Inc., PerkinElmer Inc, Bio-Rad Laboratories Inc, QIAGEN N.V., Evotec SE, Shanghai ChemPartner Co. Ltd., Aragen Life Sciences Limited, GenScript Biotech Corporation, BGI Genomics Co. Ltd., NeoGenomics Laboratories Inc, ARUP Laboratories, Syngene International Limited, BioDuro-Sundia, Ambry Genetics Corporation, Selvita, Crown Bioscience International, CENTOGENE N.V., Oncodesign Services, Reaction Biology Corporation

Global Cancer Immunotherapy Drug Discovery Outsourcing Market Trends and Insights

Major companies operating in the cancer immunotherapy drug discovery outsourcing market are adopting a strategic partnerships approach to accelerate the development of novel therapies. Strategic partnerships propel the growth of the cancer immunotherapy drug discovery outsourcing market by enabling access to advanced technologies, specialized expertise, and integrated services, thereby reducing development timelines and improving the efficiency of bringing innovative cancer immunotherapies to the clinic. For instance, in September 2025, Charles River Laboratories, a US-based contract research organization, partnered with the Parker Institute for Cancer Immunotherapy, a US-based non-profit cancer research institute, to accelerate the development of novel cancer therapies. The collaboration focuses on enhancing preclinical testing and manufacturing capabilities for cutting-edge cell and gene therapies. By combining Charles River’s expertise in contract research with the Parker Institute’s immunotherapy programs, the partnership aims to bring innovative cancer treatments to patients more efficiently.

Regional Insights

North America was the largest region in the cancer immunotherapy drug discovery outsourcing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cancer Immunotherapy Drug Discovery Outsourcing Market?

The cancer immunotherapy drug discovery outsourcing market includes revenues earned by entities by providing services such as preclinical testing, clinical trial support, and biomarker discovery. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cancer Immunotherapy Drug Discovery Outsourcing Market Report 2026?

The cancer immunotherapy drug discovery outsourcing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cancer immunotherapy drug discovery outsourcing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.